Stayble proposes voluntary liquidation – aims to sell intellectual property assets
Research company Stayble Therapeutics has convened an extraordinary general meeting on May 7 to decide on voluntary liquidation, or alternatively, continued operations. The company, which develops injectable treatments for chronic back pain, has for some time unsuccessfully sought partnerships and financing to advance the STA363 project. The board is therefore proposing liquidation with the aim…

